Ontology highlight
ABSTRACT: Arnica montana L. (Arnica) has a long history of use in treating inflammation and soft tissue injury, yet its immunomodulatory mechanisms remain largely unexplored. In this study, we investigated the effects of distinct Arnica extracts - derived from different plant parts (root or whole plant) and manufacturing processes - on primary human T cells. We also compared their effects with those of the pure compounds helenalin and thymol. All extracts inhibited T cell activation and proliferation. This could be traced back to reduced IL-2 responsiveness due to decreased CD25 (IL‑2Ra chain) expression, accompanied by reduced IL-2 production. Transcriptomic analysis (nCounter) and gene set enrichment revealed that the extracts target key T cell receptor (TCR) signaling pathways. Mechanistically, the hydroethanolic root extract selectively inhibited NFκB DNA binding, while the aqueous fermented extract predominantly suppressed NFAT-dependent gene expression. The hydroethanolic whole plant extract exerted a moderate effect on both pathways. These findings identify Arnica extracts as promising modulators of human TCR signaling and support their potential in regulating T cell-driven inflammatory responses, with implications for muscle healing and chronic inflammatory diseases.
INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase
PROVIDER: MTBLS11351 | MetaboLights | 2025-09-16
REPOSITORIES: MetaboLights
| Action | DRS | |||
|---|---|---|---|---|
| 2_neg.RAW | Raw | |||
| 3_neg.RAW | Raw | |||
| 5_neg.RAW | Raw | |||
| a_MTBLS11351_LC-MS_negative_reverse-phase_metabolite_profiling.txt | Txt | |||
| a_MTBLS11351_LC-MS_positive_reverse-phase_metabolite_profiling.txt | Txt |
Items per page: 5 1 - 5 of 9 |